Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 2.65 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2026-03-31
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-03-31 was 6.00K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2025 was 2.65K shares, a 228.00% increase from fiscal 2024.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2024 was 807.00 shares, a 98.64% decline from fiscal 2023.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2023 was 59.45K shares, a 4204.85% increase from fiscal 2022.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2022 was 1.38K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | 2.65K shares 10-K · filed 2026-03-31 | ||
| 2024-12-31 | 807.00 shares 10-K · filed 2026-03-31 | 12.10K shares 10-K · filed 2025-02-27 | |
| 2023-12-31 | 59.45K shares 10-K · filed 2025-02-27 | ||
| 2022-12-31 | 1.38K shares 10-K · filed 2024-03-28 | ||
| 2020-12-31 | 28.94K shares 10-K · filed 2022-03-31 | 434.11K shares 10-K · filed 2021-03-19 | |
| 2019-12-31 | 5.00K shares 10-K · filed 2021-03-19 | ||
| 2018-03-31 | 6.00K shares 10-Q · filed 2018-05-11 | ||
| 2016-12-31 | 126.52K shares 10-K · filed 2017-03-24 | ||
| 2015-12-31 | 14.00K shares 10-K · filed 2017-03-24 | ||
| 2014-12-31 | 21.34K shares 10-K · filed 2016-03-30 | ||
| 2013-12-31 | 444.00 shares 10-K · filed 2016-03-30 | -444.00 shares 10-K · filed 2014-03-13 | |
| 2012-12-31 | 9.13K shares 10-K · filed 2015-03-12 | -41.11K shares 10-K · filed 2013-03-18 | |
| 2011-12-31 | -14.93K shares 10-K · filed 2014-03-13 | -67.20K shares 10-K · filed 2013-03-18 | |
| 2010-12-31 | -92.28K shares 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |